IMRT (intensity modulated radiation therapy)

RADIATION4 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Centre Francois Baclesse, UNC Lineberger Comprehensive Cancer Center, Tata Memorial Centre

Conditions

Malignant GliomasMalignant Neoplasm of Anal CanalPARP InhibitorRadiotherapyRectal CancerSquamous Cell Carcinoma of Head and Neck

Phase 1

Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

Active, not recruitingNCT03212742

Centre Francois BaclesseMalignant Gliomas, PARP Inhibitor, Radiotherapy

Start: 2017-09-04End: 2026-12-31Target: 91Updated: 2025-12-04

Phase 2

Chemoradiation or Brachytherapy for Rectal Cancer

CompletedNCT02017704

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsRectal Cancer

Start: 2014-06-12End: 2023-01-31Updated: 2023-10-17

Pembrolizumab Plus Olaparib in LA-HNSCC

Active, not recruitingNCT05366166

UNC Lineberger Comprehensive Cancer CenterSquamous Cell Carcinoma of Head and Neck

Start: 2022-09-02End: 2030-11-21Updated: 2026-01-28

Unknown Phase

IMRT Versus IMPT With Concurrent Chemotherapy for Locally Advanced Anal Canal Cancer

RecruitingNCT06630793

Tata Memorial CentreMalignant Neoplasm of Anal Canal

Start: 2025-03-18End: 2032-05-01Target: 108Updated: 2025-04-08

Related Papers

Abstract A008: Imaging response to induction PD-1 and PARP inhibition in patients with locally advanced head and neck squamous cell carcinoma

Clinical Cancer Research2025-01-26

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade glioma patients: OLA-TMZ-RTE-01.

Journal of Clinical Oncology2023-06-011 citations

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.

2019-03-0487 citations

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high-grade gliomas patients: OLA-TMZ-RTE-01

Annals of Oncology2018-10-01